Adel is a Korean biotech company developing novel innovative approach to neurodegenerative diseases like Alzheimer and Parkinson diseases. ADTAC (Authophagy Degradation TArgeting Chimera) is also one of the main strategy. Adel is seeking new opportunities for co-development and in/out lincensing.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ADEL-Y01
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
